Summary & Overview
HCPCS J1569: Immune Globulin (Gammagard Liquid), 500 mg Injection
HCPCS Level II code J1569 denotes a 500 mg vial of non-lyophilized immune globulin (Gammagard liquid) used for therapeutic immune globulin administration. This code is nationally relevant as immune globulin therapies are widely used for primary and secondary immunodeficiencies, certain autoimmune disorders, and other indications where passive immunity is provided. Accurate coding for these products affects billing clarity, inventory tracking, and patient cost-sharing across payers.
Key payers covered include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks for utilization and coverage patterns, an overview of billing and site-of-service implications, and context on clinical usage of liquid immune globulin formulations. The publication outlines common modifiers and claims considerations associated with administering an infused biologic, and highlights areas where policy updates or payer-specific rules frequently affect reimbursement and documentation.
This summary is intended for national audiences including billing professionals, clinical administrators, and policy analysts seeking concise guidance on how HCPCS Level II code J1569 is used in practice, what to expect in payer interactions, and where to focus documentation to support claims adjudication.
Billing Code Overview
HCPCS Level II code J1569 represents an injection of immune globulin (gammagard liquid), non-lyophilized, 500 mg. This code is used to report administration of a liquid formulation of immune globulin indicated for immune deficiency or other clinical uses for which intravenous or subcutaneous immunoglobulin therapy is appropriate.
Service type: Therapeutic biologic injection (immune globulin administration).
Typical site of service: Infusion center, outpatient clinic, or hospital outpatient department.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A typical adult patient with primary immunodeficiency or hypogammaglobulinemia presents to an outpatient infusion center for replacement therapy. The ordering physician documents diagnosis and weight-based dosing; pharmacy dispenses J1569 (immune globulin, Gammagard liquid) in 500 mg vial increments. Nursing obtains informed consent, verifies allergy history, establishes IV access, and administers the infusion per institution protocol with pre-medications as indicated. Vital signs are monitored before, during, and after infusion to detect infusion reactions. The clinical workflow includes: physician order entry, insurance eligibility and prior authorization check, pharmacy compounding and verification, nursing administration and documentation of lot numbers and volumes, and post-infusion observation and discharge instructions. Billing is submitted using the HCPCS code J1569 with appropriate modifier(s) to reflect service circumstances and payer requirements.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug amount discarded/not administered | Report when a portion of the immune globulin vial is discarded (e.g., partial vial wasted) per payer rules. |